Dr. Martin Picard

And so there's this one trial that was published in the New England Journal last year, and they show, as expected, if you block GDF-15 with a monoclonal antibody, people don't feel as terrible.

And they eat a little more, and they don't lose as much weight.

Right?

So it's basically if you're sick in a hospital, you have cancer, you're getting chemo, you don't want to eat.

And energetically, I suspect this is the right thing to do because you're saving 10%, 15% of your energy budget, reallocating it to healing processes, your immune system, whatever the body needs to survive that challenge.

Now you're kind of depriving the brain of that signal.

So people actually don't lose as much weight.

So then that trial said success.

If you look at the fine print and you look at the table where they report mortality, mortality was double in people who were receiving the drug.

That trial was not powered to detect mortality as a primary outcome.

It was powered to detect changes in body weight.

So that didn't end up being a main finding.

But if this is real...

right?

You're preventing people from losing weight and they feel a little less nauseous, but there are twice as many people who died during that trial.

And recently there's another trial, large-scale trial for heart failure that looked at this, using this antibody to block, because when the heart struggles, dilated cardiomyopathy or congestive heart failure,

Energetically, it's really demanding for the heart to be pushing against high blood pressure or to be failing, right?

So there's an energetic stress in the heart at that point.

GDF-15 goes through the roof.

So now people know in cardiology, GDF-15 is a really good marker of heart failure.